Pharsight

1. Bynfezia Pen patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10342850	SUN PHARM	Octreotide injection	May, 2038 (14 years from now)

Market Authorisation Date: 28 January, 2020

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)	SOLUTION;SUBCUTANEOUS	Prescription

BYNFEZIA PEN family patents

2. Mycapssa patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9566246	CHIESI	Pharmaceutical compositions and related methods of delivery	Sep, 2029 (5 years from now)
US8329198	CHIESI	Pharmaceutical compositions and related methods of delivery	Sep, 2029 (5 years from now)
US9265812	CHIESI	Pharmaceutical compositions and related methods of delivery	Sep, 2029 (5 years from now)
US8535695	CHIESI	Pharmaceutical compositions and related methods of delivery	Sep, 2029 (5 years from now)
US10238709	CHIESI	Method of treating diseases	Feb, 2036 (11 years from now)
US11510963	CHIESI	Method of treating diseases	Feb, 2036 (11 years from now)
US10695397	CHIESI	Method of treating diseases	Feb, 2036 (11 years from now)
US11052126	CHIESI	Method of treating diseases	Feb, 2036 (11 years from now)
US11338011	CHIESI	Method of treating diseases	Feb, 2036 (11 years from now)
US11141457	CHIESI	Oral octreotide therapy and contraceptive methods	Dec, 2040 (16 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Jun 26, 2023

Market Authorisation Date: 26 June, 2020

Treatment: Use of oral octreotide for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide; Use of oral octreotide for long-term main...

Dosage: CAPSULE, DELAYED RELEASE;ORAL

Strength	Dosage	Availability
EQ 20MG BASE	CAPSULE, DELAYED RELEASE;ORAL	Prescription

MYCAPSSA family patents

3. Sandostatin patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5753618	NOVARTIS	Somatostatin analogue composition and use in treating breast cancer	May, 2015 (8 years ago)
US5753618 (Pediatric)	NOVARTIS	Somatostatin analogue composition and use in treating breast cancer	Nov, 2015 (8 years ago)

Market Authorisation Date: 21 October, 1988

Treatment: NA

Dosage: INJECTABLE;INJECTION

Strength	Dosage	Availability
EQ 0.2MG BASE/ML Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	INJECTABLE;INJECTION	Discontinued
EQ 0.05MG BASE/ML	INJECTABLE;INJECTION	Prescription
EQ 1MG BASE/ML Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	INJECTABLE;INJECTION	Discontinued
EQ 0.1MG BASE/ML	INJECTABLE;INJECTION	Prescription
EQ 0.5MG BASE/ML	INJECTABLE;INJECTION	Prescription

SANDOSTATIN family patents

4. Sandostatin Lar patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5538739	NOVARTIS	Sustained release formulations of water soluble peptides	Jul, 2013 (10 years ago)
US5538739 (Pediatric)	NOVARTIS	Sustained release formulations of water soluble peptides	Jan, 2014 (10 years ago)
US5639480	NOVARTIS	Sustained release formulations of water soluble peptides	Jun, 2014 (9 years ago)
US5688530	NOVARTIS	Sustained release formulations of water soluble peptides	Nov, 2014 (9 years ago)
US5639480 (Pediatric)	NOVARTIS	Sustained release formulations of water soluble peptides	Dec, 2014 (9 years ago)
US5688530 (Pediatric)	NOVARTIS	Sustained release formulations of water soluble peptides	May, 2015 (8 years ago)
US5922682	NOVARTIS	Polyol esters, their preparation and use in depot forms of pharmacologically active agents	Jul, 2016 (7 years ago)
US5922338	NOVARTIS	Polyol esters, their preparation and use in depot forms of pharmacologically active agents	Jul, 2016 (7 years ago)
US5922338 (Pediatric)	NOVARTIS	Polyol esters, their preparation and use in depot forms of pharmacologically active agents	Jan, 2017 (7 years ago)
US5922682 (Pediatric)	NOVARTIS	Polyol esters, their preparation and use in depot forms of pharmacologically active agents	Jan, 2017 (7 years ago)

Market Authorisation Date: 25 November, 1998

Treatment: Acromegaly